Literature DB >> 24922494

Clinical predictors of ketamine response in treatment-resistant major depression.

Mark J Niciu1, David A Luckenbaugh, Dawn F Ionescu, Sara Guevara, Rodrigo Machado-Vieira, Erica M Richards, Nancy E Brutsche, Neal M Nolan, Carlos A Zarate.   

Abstract

OBJECTIVE: The N-methyl-D-aspartate receptor antagonist ketamine has rapid antidepressant effects in treatment-resistant major depressive disorder (MDD) and bipolar depression. Clinical predictors may identify those more likely to benefit from ketamine within clinically heterogeneous populations.
METHOD: Data were analyzed from 4 studies of treatment-resistant inpatients with DSM-IV-TR-diagnosed MDD or bipolar I or II depression. Patients who were currently experiencing a moderate-to-severe major depressive episode were enrolled between November 2004 and March 2013. All subjects received a single subanesthetic (0.5 mg/kg) ketamine infusion over 40 minutes. Patients were analyzed at the 230-minute postinfusion time point (n = 108), at day 1 (n = 82), and at day 7 (n = 71). Univariate Pearson correlations were performed for each variable with percent change from baseline in the 17-item Hamilton Depression Rating Scale (HDRS). Multivariate linear regression was then conducted for statistically significant predictors (P ≤ .05, 2-tailed).
RESULTS: Higher body mass index correlated with greater HDRS improvement at 230 minutes (standardized β = -0.30, P = .004) and at day 1 (standardized β = -0.37, P = .001), but not at day 7 (standardized β = -0.18, P = .10). Family history of an alcohol use disorder in a first-degree relative was associated with greater HDRS improvement at day 1 (standardized β = -0.27, P = .014) and day 7 (standardized β = -0.41, P < .001). No prior history of suicide attempt(s) was associated with greater improvement only at day 7 (standardized β = 0.28, P = .01). The overall statistical model explained 13%, 23%, and 36% of HDRS percent change variance at 230 minutes, day 1, and day 7, respectively.
CONCLUSIONS: Despite its post hoc nature, this study identified several clinical correlates of ketamine's rapid and durable antidepressant effects. Further investigation of these relationships is critical for individualized treatment of depression. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24922494      PMCID: PMC4310499          DOI: 10.4088/JCP.13m08698

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  38 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics.

Authors:  J H Krystal; I L Petrakis; E Webb; N L Cooney; L P Karper; S Namanworth; P Stetson; L A Trevisan; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1998-04

3.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

4.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

Authors:  Maura L Furey; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-10

5.  Clinical predictors of acute response with olanzapine in psychotic mood disorders.

Authors:  C A Zarate; R Narendran; M Tohen; J J Greaney; A Berman; S Pike; A Madrid
Journal:  J Clin Psychiatry       Date:  1998-01       Impact factor: 4.384

6.  Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders.

Authors:  Gabriela V Obrocea; Robert M Dunn; Mark A Frye; Terence A Ketter; David A Luckenbaugh; Gabriele S Leverich; Andrew M Speer; Elizabeth A Osuch; Kamal Jajodia; Robert M Post
Journal:  Biol Psychiatry       Date:  2002-02-01       Impact factor: 13.382

7.  Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.

Authors:  Laura E Phelps; Nancy Brutsche; Jazmin R Moral; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2008-11-08       Impact factor: 13.382

8.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

9.  Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior.

Authors:  Gunter Schumann; Monika Johann; Josef Frank; Ulrich Preuss; Norbert Dahmen; Manfred Laucht; Marcella Rietschel; Dan Rujescu; Anbarasu Lourdusamy; Toni-Kim Clarke; Kristina Krause; Anne Dyer; Martin Depner; Stefan Wellek; Jens Treutlein; Armin Szegedi; Ina Giegling; Sven Cichon; Dorothea Blomeyer; Andreas Heinz; Simon Heath; Mark Lathrop; Norbert Wodarz; Michael Soyka; Rainer Spanagel; Karl Mann
Journal:  Arch Gen Psychiatry       Date:  2008-07

10.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

View more
  50 in total

1.  Ketamine for depression: evidence, challenges and promise.

Authors:  Carlos A Zarate; Mark J Niciu
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

Review 2.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

3.  Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning-Based Treatment Outcome in Obsessive-Compulsive Disorder: A Pilot Study.

Authors:  Omer Linkovski; Michael G Wheaton; Jordana Zwerling; Zagaa Odgerel; Peter van Roessel; Maria Filippou-Frye; Anthony Lombardi; Brianna Wright; Shari A Steinman; Helen Blair Simpson; Francis Lee; Carolyn I Rodriguez
Journal:  J Clin Psychopharmacol       Date:  2019 Jan/Feb       Impact factor: 3.153

4.  Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.

Authors:  N B Lundin; M J Niciu; D A Luckenbaugh; D F Ionescu; E M Richards; J L Vande Voort; N E Brutsche; R Machado-Vieira; C A Zarate
Journal:  Pharmacopsychiatry       Date:  2014-06-23       Impact factor: 5.788

Review 5.  Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.

Authors:  Lisa M Monteggia; Carlos Zarate
Journal:  Curr Opin Neurobiol       Date:  2015-01-03       Impact factor: 6.627

6.  Characterizing the course of suicidal ideation response to ketamine.

Authors:  Elizabeth D Ballard; Julia S Yarrington; Cristan A Farmer; Erica Richards; Rodrigo Machado-Vieira; Bashkim Kadriu; Mark J Niciu; Peixiong Yuan; Lawrence Park; Carlos A Zarate
Journal:  J Affect Disord       Date:  2018-07-30       Impact factor: 4.839

7.  New use for an old drug: oral ketamine for treatment-resistant depression.

Authors:  Kevin M Swiatek; Kim Jordan; Julie Coffman
Journal:  BMJ Case Rep       Date:  2016-08-03

8.  Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Authors:  Marlene P Freeman; George I Papakostas; Bettina Hoeppner; Erica Mazzone; Heidi Judge; Cristina Cusin; Sanjay Mathew; Gerard Sanacora; Dan Iosifescu; Charles DeBattista; Madhukar H Trivedi; Maurizio Fava
Journal:  J Psychiatr Res       Date:  2019-01-08       Impact factor: 4.791

Review 9.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

10.  Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.

Authors:  Elizabeth D Ballard; David A Luckenbaugh; Erica M Richards; Tessa L Walls; Nancy E Brutsché; Rezvan Ameli; Mark J Niciu; Jennifer L Vande Voort; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2015-06-16       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.